Diphtheria + tetanus + acellular pertussis vaccine

PBAC's latest decision on Diphtheria + tetanus + acellular pertussis vaccine: Noted (2014). Considered for Prevention of pertussis as an 18-month booster dose in infants.

Eligible population

Infants aged approximately 18 months receiving a DTPa booster dose for pertussis prevention.

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Vaccine effectiveness

Key trials

Quinn 2014, Quinn 2011, Wood 2012, Nolan 2009, GSK 213503/046, Marshall 2006, APV-015B, APV-020B, APV-027B, Sheridan 2014, Rendi-Wagner 2006, Bisgard 2005, Lugauer 2002, De Serres 2001

Comparator

no booster at 18 months (current vaccination schedule)

Economic model

CUA

Eligible patients/year

307,934

ICER note

The document does not provide an explicit ICER value. The economic evaluation is a cost-utility analysis but the submission did not calculate absolute QALYs (text cuts off at 6.18).

Similar precedents

• Pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (dtap)
  similarity 0.86
• Diphtheria, tetanus, acellular pertussis vaccine (dtpa)
  similarity 0.77
• Diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b conjugate vaccine
  similarity 0.71
• Diphtheria and tetanus toxoids combined with pertussis vaccine-acellular
  similarity 0.71
• Dtpa-hepb-ipv-hib vaccine
  similarity 0.71
• Quadrivalent influenza vaccine (split virion, inactivated)
  similarity 0.62